Core Insights - The China Securities Medicine and Medical Device Innovation Index (931484) shows mixed performance among its constituent stocks, with New and Achieve leading the gains at 3.63% [1] - The Medical Innovation ETF (516820) has seen a net inflow of 12.6971 million yuan over the past three days, with a peak single-day inflow of 6.1732 million yuan [1] - The current phase of brain-computer interface technology is described as an explosive period, with multiple countries, including China, accelerating their strategic positioning in global brain science [1] - AI is transitioning from a supportive role to becoming a core driver of value reconstruction and efficiency revolution in the medical industry, impacting various sectors such as medical imaging and drug development [1] Industry Overview - The Medical Innovation ETF closely tracks the China Securities Medicine and Medical Device Innovation Index, which selects 30 profitable and growth-oriented companies in the pharmaceutical and medical device sectors [2] - As of January 30, 2026, the top ten weighted stocks in the index include WuXi AppTec, Mindray, and Hengrui Medicine, collectively accounting for 63.9% of the index [2]

Group 1 - The core viewpoint of the news highlights the growth and investment opportunities in the brain-computer interface (BCI) market, particularly in China, with significant funding and technological advancements being made by domestic companies [1][2] - The China Medical and Medical Device Innovation Index (931484) has shown a positive performance, with a 0.78% increase, and notable gains in constituent stocks such as TeBao Bio and XinHe Cheng [1] - The global brain-computer interface market is projected to reach approximately $2.62 billion in 2024, with an expected growth to $2.94 billion in 2025 and a compound annual growth rate of 17.35% over the next decade [2] Group 2 - The Chinese brain-computer interface market is anticipated to grow from 3.2 billion yuan in 2024 to 6.14 billion yuan by 2028, indicating a strong domestic market potential [2] - Recent funding of 300 million yuan in A+ round financing for ZhiRan Medical will be utilized for large-scale clinical trials and product iterations, marking a significant step in the application of invasive brain-computer interfaces [1] - The top ten weighted stocks in the China Medical and Medical Device Innovation Index account for 63.9% of the index, with companies like WuXi AppTec and Mindray Medical leading the list [2]

创新药概念局部活跃，消息面上，新修订的《中华人民共和国药品管理法实施条例》将于5月15日起施 行。国家药监局表示，这是条例实施二十多年来，首次全面修订。支持以临床价值为导向研究和创制新 药，提升仿制药质量和疗效。 中信证券研报称，2026年1月，阿里健康、京东健康两家头部医药电商平台相继正式发布面向医生的AI 医疗应用产品。看好头部医药电商平台凭借上游药企、下游C端用户资源，以及其母公司具备的AI基模 能力与产品能力，在ToD AI医疗应用领域脱颖而出，并率先跑通商业模式，实现AI医疗对主业的增收 赋能。 医疗创新ETF紧密跟踪中证医药及医疗器械创新指数，中证医药及医疗器械创新指数从医药卫生行业的 上市公司中，选取30只盈利能力较好且具备一定成长性和研发创新能力的上市公司证券作为指数样本， 以反映兼具盈利性与成长性的医药及医疗器械上市公司证券的整体表现。 截至2026年1月28日 11:09，中证医药及医疗器械创新指数(931484)成分股方面涨跌互现，兴齐眼药领涨 1.42%，新和成上涨1.27%，片仔癀上涨0.27%；英科医疗领跌2.47%，华兰生物下跌2.22%，恩华药业下 跌2.22%。医疗创新ETF ...

截至2026年1月21日 13:11，中证医药及医疗器械创新指数(931484)上涨0.03%，成分股特宝生物上涨 3.38%，甘李药业上涨2.24%，英科医疗上涨1.70%，康龙化成上涨1.23%，大博医疗上涨1.16%。医疗创 新ETF(516820)多空胶着，最新报价0.37元。 医疗创新ETF紧密跟踪中证医药及医疗器械创新指数，中证医药及医疗器械创新指数从医药卫生行业的 上市公司中，选取30只盈利能力较好且具备一定成长性和研发创新能力的上市公司证券作为指数样本， 以反映兼具盈利性与成长性的医药及医疗器械上市公司证券的整体表现。 数据显示，截至2025年12月31日，中证医药及医疗器械创新指数(931484)前十大权重股分别为药明康 德、恒瑞医药、迈瑞医疗、爱尔眼科、片仔癀、新和成、华东医药、康龙化成、艾力斯、甘李药业，前 十大权重股合计占比63.75%。 风险提示：基金有风险，投资需谨慎。基金管理人承诺以诚实信用、勤勉尽责的原则管理和运用基金资 产，但不保证本基金一定盈利，也不保证最低收益。基金管理人提醒投资人基金投资的"买者自负"原 则，在做出投资决策后，基金运营状况与基金净值变化引致的投资风险，由 ...

Core Viewpoint - The flu epidemic level in China is rising, leading to increased activity in the anti-flu concept stocks, with Haiwang Biological hitting the daily limit up [1] Group 1: Market Activity - The Medical Innovation ETF (516820.SH) is down 0.81%, with mixed performance among constituent stocks; Dong'e Ejiao (000423) leads with a 0.91% increase, while Kanghong Pharmaceutical (002773) falls by 2.43% [1] - The latest data from the Chinese Center for Disease Control and Prevention shows that the flu positivity rate among outpatient and emergency cases is close to 45%, indicating a medium epidemic level, with some provinces reaching a high epidemic level [1] - The Medical Innovation ETF has seen a net outflow of 2.582 million yuan recently, but over the past 20 trading days, there have been 14 days of net inflow totaling 99.49 million yuan [1] Group 2: Investment Insights - Guosen Securities notes that the current valuations in the medical device and pharmacy sectors already reflect risks from domestic and international policies, suggesting a focus on undervalued stocks with potential highlights or marginal changes [1] - The Medical Innovation ETF selects 30 pharmaceutical blue-chip stocks, covering key sectors such as innovative drugs (34%), CXO (17%), medical devices (13%), and consumer healthcare (11%), indicating a potential for short-term gains in lower-valued medical core assets [1] - The pharmaceutical sector is experiencing significant differentiation, with innovative drug valuations being high (historically at the 88th percentile), while CXO, medical devices, and consumer healthcare sectors show potential for rebound [1]

Group 1 - The medical device sector is experiencing a strong upward trend, with the Medical Innovation ETF (516820.SH) rising by 0.27% and key stocks such as Haier Medical (002653) and Mindray Medical (300760) increasing by 4.05% and 4.04% respectively [1] - Recent measures from cities like Beijing and Shanghai aim to support the high-quality development of the medical device industry, focusing on various aspects such as clinical research, registration, production, and international expansion [1] - CITIC Construction Investment Securities remains optimistic about structural investment opportunities in the medical device sector by 2026, highlighting the potential for performance improvement and valuation recovery among leading companies in the industry [1] Group 2 - The Medical Innovation ETF has seen a net inflow of 5.5148 million yuan recently, with a total of 33.8573 million yuan net inflow over the past 10 trading days, indicating strong investor interest [2] - The ETF focuses on 30 pharmaceutical blue-chip stocks, covering key sectors such as innovative drugs (34%), CXO (17%), medical devices (13%), and consumer healthcare (11%), suggesting a diversified investment approach [2] - The current pharmaceutical sector shows significant differentiation, with high valuations in innovative drugs while sectors like CXO, medical devices, and consumer healthcare present potential for rebound [2]

Group 1 - The core viewpoint indicates that the medical innovation sector is experiencing a downturn, with significant declines in stocks such as Kanglong Chemical, which fell by 5.37%, and others like Sanofi and Kanghong Pharmaceutical also showing notable decreases [1] - The Medical Innovation ETF has decreased by 1.56%, with the latest price at 0.38 yuan, reflecting the overall market sentiment in the medical sector [1] - The introduction of heterogeneous robots in sanitation and healthcare is expected to create new development opportunities in the medical innovation field, as the domestic industrial chain continues to demonstrate advantages [1] Group 2 - The CSI Medical and Medical Device Innovation Index consists of 30 listed companies selected for their profitability, growth potential, and R&D capabilities, aiming to reflect the overall performance of profitable and growth-oriented companies in the medical and medical device sectors [2] - As of October 31, 2025, the top ten weighted stocks in the CSI Medical and Medical Device Innovation Index account for 64.12% of the index, with companies like WuXi AppTec and Hengrui Medicine leading the list [2] - The medical sector's valuation is considered to be at a low point compared to the last decade, with expectations for recovery driven by innovative drugs and CXO trends [1]

Core Insights - The healthcare innovation sector is showing positive momentum, with the China Securities Medicine and Medical Device Innovation Index (931484) rising by 0.31% as of November 14, 2025, and several key stocks, including Sanofi and Ganli Pharmaceutical, experiencing significant gains [1] Group 1: Market Performance - The China Securities Medicine and Medical Device Innovation Index has seen a 0.31% increase, with notable stock performances: Sanofi up 4.64%, Ganli Pharmaceutical up 3.28%, and Jiutian Pharmaceutical up 1.83% [1] - The Medical Innovation ETF (516820) has also risen by 0.26%, marking its third consecutive increase [1] Group 2: Clinical Developments - AstraZeneca announced successful Phase III clinical trials for Baxdrostat, which significantly reduced 24-hour average systolic blood pressure in patients with resistant hypertension over 12 weeks, indicating a new treatment pathway for hypertension [1] Group 3: Industry Trends - According to Dongfang Caifu Securities, the pharmaceutical industry showed improvement in Q3 2025, with the medical device sector experiencing a turning point, achieving positive year-on-year revenue growth and a notable narrowing of net profit declines [1] - The CXO sector performed exceptionally well in the first three quarters of 2025, with medical R&D outsourcing revenue increasing by 12.2% and net profit rising by 56.8%, particularly in ADC CDMO and peptide CDMO fields [2] - The index reflects the performance of 30 profitable and growth-oriented companies in the pharmaceutical and medical device sectors, with the top ten stocks accounting for 64.12% of the index [2]

Core Insights - The Medical Innovation ETF (516820) experienced a net financing purchase of 3.9261 million yuan on November 11, 2025, with a total financing balance of 62.306 million yuan, marking a continuous net purchase over the last three trading days totaling 5.1496 million yuan [1][2]. Financing Activity Summary - On November 11, 2025, the financing net purchase was 3.9261 million yuan, with a financing balance of 62.306 million yuan, reflecting a 6.73% increase from the previous day [2][3]. - The financing balance on November 10, 2025, was 58.3799 million yuan, with a net purchase of 0.6966 million yuan, indicating a 1.21% increase [2][3]. - On November 7, 2025, the financing balance was 57.6832 million yuan, with a net purchase of 0.5269 million yuan, showing a 0.92% increase [2][3]. - The financing balance on November 6, 2025, was 57.1564 million yuan, with a net decrease of 0.6613 million yuan, reflecting a -1.14% change [2][3]. - The financing balance on November 5, 2025, was 57.8177 million yuan, with a negligible net decrease of 0.00114 million yuan, indicating a -0.02% change [2][3].

Core Insights - The Medical Innovation ETF (516820) experienced a net financing purchase of 2.55 million yuan on October 14, 2025, with a total financing balance of 53.38 million yuan, indicating a positive investor sentiment towards the ETF [1][2][3] Financing Activity Summary - On October 14, 2025, the financing buy amounted to 8.15 million yuan, while financing repayment was 5.60 million yuan, resulting in a net financing purchase of 2.55 million yuan [1] - Over the past three trading days, the cumulative net financing purchase reached 3.70 million yuan, with 14 out of the last 20 trading days showing net financing purchases [1] - The financing balance increased by 5.01% from the previous day, reflecting a growing interest in the ETF [2][3] Trading Data Overview - The financing balance on October 14, 2025, was 53.38 million yuan, up from 50.83 million yuan on October 13, 2025 [2][3] - The net financing purchases for the previous trading days were as follows: 1.15 million yuan on October 13, 0.74 million yuan on October 10, and 0.17 million yuan on October 9 [2] - The financing balance has shown a consistent upward trend, with a notable increase of 2.32% on October 13 and a minimal increase of 0.04% on October 10 [3]